ArticleJACC. Case reports2025
Hybrid Revascularization Approach in a Patient With Cancer Metastatic to the Sternum.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHybrid revascularization is a less invasive approach to conventional open-chest coronary artery bypass graft surgery for patients with multivessel coronary arterial disease. However, this is infrequently performed because of technical demands, logistical challenges, and concerns for long-term vessel patency. CASE SUMMARY: A 68-year-old man with a history of prostate cancer with bony metastasis presented with accelerated angina. Left heart catheterization revealed multivessel coronary disease. The patient underwent staged hybrid surgical and percutaneous revascularization treatment. Ultimately, the intervention was successful, and the patient had symptomatic relief with successful recovery to baseline function. DISCUSSION: This case provides insight into the efficacy and application of an individualized hybrid approach in a high-risk patient with comorbidities. TAKE-HOME MESSAGE: Hybrid revascularization is safe and can be considered on an individual basis for patients with complex medical comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.